Yıl: 2021 Cilt: 12 Sayı: 27 Sayfa Aralığı: 52 - 58 Metin Dili: Türkçe İndeks Tarihi: 14-02-2022

COVID-19 Sürecinde Hipertansiyon Hastaları İçin Neler Yapalım?

Öz:
Yeni Tip Koronavirüs-COVID-19 enfeksiyonunda hipertansiyon; en sık gözlenen komorbid hastalıklardan biri olup, mortalite için önemli bir risk faktörüdür. Hipertansiyonlu hastalar zayıf prognoza sahiptir, fakat hipertansiyonun yaş ve diğer risk faktörlerinden bağımsız olarak yeni enfeksiyon riskini veya olumsuz sonuçları arttırdığına dair bir kanıt yoktur. Pandemi sürecinin başında, hipertansiyon tedavisinde sıklıkla kullanılan bazı ilaçların COVID-19’a bağlı morbidite ve mortaliteyi arttırdığı yönünde tartışmalı açıklamalar yapılmıştır. Ancak bu açıklamaları destekleyen herhangi bir bilimsel kanıt bulunmamakta ve ilaç tedavisine devam edilmesi gerekliliği vurgulanmaktadır. Fiziksel ve psikolojik iyilik halinin izlenmesi ve sürdürülmesi girişimleri pandemi sırasında hasta yönetim stratejilerinde dikkate alınması gereken en önemli konulardır. Hipertansiyonlu hastaların izleyen dönemdeki yönetimleri için de evde kan basıncı izleme stratejileri sosyal mesafe sürdürülerek iyi kan basıncı kontrolünü sağlamayı kolaylaştıracaktır. Bu derleme makalenin amacı, literatürde COVID-19 pandemisi ve hipertansiyon ilişkisini araştıran çalışmaları irdeleyerek, hipertansiyonun etkin yönetimi konusunda kılavuz temelli en son bilgileri aktarmak ve bu süreçte hipertansiyonun etkin yönetimini sürdürebilmek için hemşirelik uygulamalarında teknolojik yaklaşımlardan yararlanılması gerekliliğini vurgulamaktır.
Anahtar Kelime:

What to Do for Patients with Hypertension During COVID-19?

Öz:
Hypertension is one of the most common comorbid diseases with the new coronavirus disease 2019 (COVID-19) and is an important risk factor for mortality. Patients with hypertension have a poor prognosis, but there is no evidence that hypertension increases the risk of new infections or adverse outcomes, regardless of age or other risk factors. At the beginning of the pandemic, controversial statements were made that some drugs frequently used in the treatment of hypertension increased morbidity and mortality owing to COVID-19. However, there is no scientific evidence to support these explanations, and the need to continue drug therapy is emphasized. Efforts to monitor and maintain physical and psychological well-being are the most important issues to be considered in patient management strategies during the pandemic. For the subsequent management of patients with hypertension, home blood pressure monitoring strategies will facilitate good blood pressure control by maintaining social distance. The purpose of this review article is to examine the studies investigating the relationship between the COVID-19 pandemic and hypertension in the literature, to convey the latest guideline-based information on the effective management of hypertension, and to emphasize the necessity of using technological approaches in nursing practices to maintain the effective management of hypertension in this process.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Türkiye Cumhuriyeti Sağlık Bakanlığı Halk Sağlığı Genel Müdürlüğü. Available from: https://covid19.saglik.gov.tr/TR66300/covid-19-nedir-.html
  • 2. Kocabay G, Çetinarslan Ö. COVID-19 pandemisinin kardiyovasküler etkileri. Kocabay G, editör. Koronavirüs Hastalığı 2019 (COVID-19) ve Kardiyovasküler Sistem. 1. Baskı. Ankara: Türkiye Klinikleri; 2020.p.1-9.
  • 3. T.C. Sağlık Bakanlığı Covıd-19 Bilgilendirme Sayfası. Available from: https://covid19.saglik.gov.tr/.
  • 4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 Novel Coronavirus in Wuhan, China. Lancet 2020;395(10223):497-506. [Crossref]
  • 5. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The incubation period of Coronavirus Disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. Ann Intern Med 2020;72(9):577-82. [Crossref]
  • 6. Ren SY, Wang WB, Hao YG, Zang HR, Wang ZC, Chen YL, et al. Stability and infectivity of coronaviruses in inanimate environments. World J Clin Cases 2020;8(8):1391-9. [Crossref]
  • 7. Şirin H, Özkan S. Dünyada ve Türkiye’de COVID-19 epidemiyolojisi. Kulak Burun Boğaz ve Baş Boyun Cerrahisi Dergisi 2020;28(Suppl):6-13. [Crossref]
  • 8. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation 2020;141(20):1648-55. [Crossref]
  • 9. Dong Y, Mo X, Hu Y, Qui X, Jiang F, Jiang Z, et al. Epidemiological characteristics of 2143 pediatric patients with 2019 Coronavirus disease in China. Pediatrics. 2020;145(6):e20200702. [Crossref]
  • 10. T.C. Sağlık Bakanlığı COVID-19 Günlük Durum Raporu 29/09/2020 Türkiye. Available from https://covid19.saglik. gov.tr/Eklenti/38819/0/covid-19-gunluk-durum-raporu- --29092020pdf.pdf?_tag1=D34DEDA4AF747A887884AB1330645EE1E0C7DF85
  • 11. Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. Int J Antimicrob Agents 2020;55(5):105955. [Crossref]
  • 12. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings in 919 patients. AJR Am J Roentgenol 2020;215(1):87-93. [Crossref]
  • 13. Zhang ZL, Hou YL, Li DT, Li FZ. Laboratory findings of COVID-19: A systematic review and meta-analysis. Scand J Clin Lab Invest 2020;80(6):441-7. [Crossref]
  • 14. Guan WJ, Ni ZY, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20. [Crossref]
  • 15. Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19): Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19), 2020. Available from https://www.cdc. gov/coronavirus/2019-ncov/hcp/clinicalguidance-management-patients.html.
  • 16. Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19): Information for Clinicians on Therapeutic Options for COVID-19 Patients, 2020. Available from https://www.cdc.gov/coronavirus/2019- ncov/hcp/ therapeutic-options.html.
  • 17. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30(3):269-71. [Crossref]
  • 18. Leung C. Clinical features of deaths in the novel coronavirus epidemic in China. Rev Med Virol 2020;30(3):e2103. [Crossref]
  • 19. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323(11):1061-9. [Crossref]
  • 20. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. China medical treatment expert group for COVID-19 (2020). Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur Respir J 2020;55:2000547 [Crossref]
  • 21. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395(10223):507-13. [Crossref]
  • 22. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA 2020;323(16):1612-4. [Crossref]
  • 23. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiology 2020;5(7):811-8. [Crossref]
  • 24. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 2020;395(10229):1054-62. [Crossref]
  • 25. Garg S, Kim L, Whitaker M, O’Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET. US Department of Health and Human Services/Centers for Disease Control and Prevention MMWR 2020;(69):15.
  • 26. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA 2020;323(13):1239-242. [Crossref]
  • 27. Lippi G, Wong J, Henry BM. Hypertension and its severity or mortality in Coronavirus Disease 2019 (COVID-19): A pooled analysis. Pol Arch Intern Med 2020;130(4):304-9. [Crossref] 28. Conversano A, Melillo F, Napolano A, Fominskiy E, Spessot M, Ciceri F, et al. RAAS inhibitors and outcome in patients with sARsCoV-2 pneumonia. A case series study. Hypertension. 2020;76(2):e10-2. [Crossref]
  • 29. Hasöksüz M, Kiliç S, Saraç F. Coronaviruses and SARSCOV-2. Turk J Med Sci 2020;50(3): 549-56. [Crossref]
  • 30. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019;17(3):181-92. [Crossref]
  • 31. Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect 2020;9(1):757-60. [Crossref]
  • 32. Yıldırım T. COVID-19 ve hipertansiyon. İçinde: Ateş K, Arıcı M, editörler. Nefroloji ve COVID-19. 1. Baskı. Ankara: Türkiye Klinikleri; 2020.s.12-6.
  • 33. Chai X, Hu L, Zhang Y, Han W, Lu Z, Ke A, et al. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. BioRxiv 2020 [Preprint]. doi: https:// doi.org/10.1101/2020.02.03.931766 [Crossref]
  • 34. Klimas J, Olvedy M, Ochodnicka-Mackovicova K, Kruzliak P, Cacanyiova S, Kristek F, et al. Perinatally administered losartan augmentsrenal ACE2 expression but not cardiac or renal mas receptor in spontaneously hypertensive rats. J Cell Mol Med 2015;19(8):1965-74. [Crossref]
  • 35. Bosso M, Thanaraj TA, Abu-Farha M, Alanbaei M, Abubaker J, Al-Mulla F. The two faces of ACE2: The role of ACE2 receptor and its polymorphisms in hypertension and COVID-19. Mol Ther Methods Clin Dev 2020;11(18):321-7. [Crossref]
  • 36. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Reninangiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med 2020;382:1653-9. [Crossref]
  • 37. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19 [Retracted]. N Engl J Med 2020;382(25):e102. [Crossref]
  • 38. Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin-converting enzyme ınhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res 2020;126(12):1671-81. [Crossref]
  • 39. Kuster G, Pfister O, Burkard T, Zhou O, Twerenbold R, Haaf P, et al. SARSCoV2: Should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19? Eur Heart J 2020;41(19):1801-3. [Crossref]
  • 40. The European Society for Cardiology. ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic. Available from: https://www.escardio.org/Education/COVID-19-and-Cardiology/ESCCOVID-19-Guidance.
  • 41. American College of Cardiology/American Heart Association. HFsA/ACC/AHA Statement Addresses Concerns Re: using RAAs Antagonists in COVID-19. Available from: https://www. acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addressesconcerns-re-using-raas-antagonists-in-covid19.
  • 42. Aktoz M, Altay H, Aslanger E, Atalar E, Atar İ, Aytekin V, et al. Türk Kardiyoloji Derneği uzlaşı raporu: COVID-19 pandemisi ve kardiyovasküler hastalıklar konusunda bilinmesi gerekenler. Turk Kardiyol Dern Ars 2020;48(Suppl 1):1-48 [Crossref]
  • 43. Ferdinand KC, Vo TN, Echols MR. State-of-the-art review: Hypertension practice guidelines in the era of COVID-19. Am J Prev Cardiol 2020;2:100038 [Crossref]
  • 44. Kario K, Morisawa Y, Sukonthasarn A, Turana Y, Chia YC, Park S, et al. COVID-19 and hypertension-evidence and practical management: Guidance from the HOPE Asia Network. J Clin Hypertens (Greenwich) 2020;22(7):1109-19. [Crossref]
  • 45. Demirağ H, Hintistan S. COVID-19’un klinik yönetimi ve hemşirelik. Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi GÜSBD 2020;9(2):222-31. [Crossref]
  • 46. Gök Metin Z. COVID-19 hastalığının fizyopatolojisi ve holistik hemşirelik yaklaşımı. Hacettepe Üniversitesi Hemşirelik Fakültesi Dergisi 2020;7(Özel Sayı):15-24. https://doi. org/10.31125/hunhemsire.775658
  • 47. Treskes RW. Effect of smartphone-enabled health monitoring devices vs regular follow-up on blood pressure control among patients after myocardial infarction A randomized clinical trial. JAMA Netw Open 2020;3(4):e202165. [Crossref]
  • 48. Members WC, Wang H, Zeng T, Wu X, Sun H. Holistic care for patients with severe coronavirus disease 2019: An expert consensus. Chinese Journal of Nursing 2020;55(3):337-42.
  • 49. Mohsen MM, Riad NA, Badawy AE, Abd El Gafar SE, Abd ElHammed BM, Eltomy EM. Tele-nursing versus routine outpatient teaching for improving arterial blood pressure and body mass index for hypertensive patients. American Journal of Nursing Research 2020;8(1):18-26.
  • 50. Lu JF, Chen CM, Hsu CY. Effect of home telehealth care on blood pressure control: A public healthcare centre model. J Telemed Telecare 2019;25(1):35-45. [Crossref]
  • 51. Bosworth HB, Olsen MK, McCant F, Harrelson M, Gentry P, Rose C., et al. Hypertension intervention nurse telemedicine study (HINTS): Testing a multifactorial tailored behavioral/ educational and a medication management intervention for blood pressure control. Am Heart J 2007;153:918-24. [Crossref]
  • 52. Lurie N, Carr BG. The role of telehealth in the medical response to disasters. JAMA Intern Med 2018;178:745-6. [Crossref]
  • 53. Khera A, Baum SJ, Gluckman TJ, Gulati M, Martin SS, Michos ED, et al. Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: A scientific statement from the American Society for Preventive Cardiology. Am J Prev Cardiol 2020;1:100009. [Crossref]
  • 54. Nishizawa M, Hoshide S, Okawara Y, Matsuo T, Kario K. Strict blood pressure control achieved using an ICT-based home blood pressure monitoring system in a catastrophically damaged area after a disaster. J Clin Hypertens (Greenwich) 2017;19:26-9. [Crossref]
APA Beyece İncazlı S, ÖZER S (2021). COVID-19 Sürecinde Hipertansiyon Hastaları İçin Neler Yapalım?. , 52 - 58.
Chicago Beyece İncazlı Seçil,ÖZER SERAP COVID-19 Sürecinde Hipertansiyon Hastaları İçin Neler Yapalım?. (2021): 52 - 58.
MLA Beyece İncazlı Seçil,ÖZER SERAP COVID-19 Sürecinde Hipertansiyon Hastaları İçin Neler Yapalım?. , 2021, ss.52 - 58.
AMA Beyece İncazlı S,ÖZER S COVID-19 Sürecinde Hipertansiyon Hastaları İçin Neler Yapalım?. . 2021; 52 - 58.
Vancouver Beyece İncazlı S,ÖZER S COVID-19 Sürecinde Hipertansiyon Hastaları İçin Neler Yapalım?. . 2021; 52 - 58.
IEEE Beyece İncazlı S,ÖZER S "COVID-19 Sürecinde Hipertansiyon Hastaları İçin Neler Yapalım?." , ss.52 - 58, 2021.
ISNAD Beyece İncazlı, Seçil - ÖZER, SERAP. "COVID-19 Sürecinde Hipertansiyon Hastaları İçin Neler Yapalım?". (2021), 52-58.
APA Beyece İncazlı S, ÖZER S (2021). COVID-19 Sürecinde Hipertansiyon Hastaları İçin Neler Yapalım?. Kardiyovasküler Hemşirelik Dergisi, 12(27), 52 - 58.
Chicago Beyece İncazlı Seçil,ÖZER SERAP COVID-19 Sürecinde Hipertansiyon Hastaları İçin Neler Yapalım?. Kardiyovasküler Hemşirelik Dergisi 12, no.27 (2021): 52 - 58.
MLA Beyece İncazlı Seçil,ÖZER SERAP COVID-19 Sürecinde Hipertansiyon Hastaları İçin Neler Yapalım?. Kardiyovasküler Hemşirelik Dergisi, vol.12, no.27, 2021, ss.52 - 58.
AMA Beyece İncazlı S,ÖZER S COVID-19 Sürecinde Hipertansiyon Hastaları İçin Neler Yapalım?. Kardiyovasküler Hemşirelik Dergisi. 2021; 12(27): 52 - 58.
Vancouver Beyece İncazlı S,ÖZER S COVID-19 Sürecinde Hipertansiyon Hastaları İçin Neler Yapalım?. Kardiyovasküler Hemşirelik Dergisi. 2021; 12(27): 52 - 58.
IEEE Beyece İncazlı S,ÖZER S "COVID-19 Sürecinde Hipertansiyon Hastaları İçin Neler Yapalım?." Kardiyovasküler Hemşirelik Dergisi, 12, ss.52 - 58, 2021.
ISNAD Beyece İncazlı, Seçil - ÖZER, SERAP. "COVID-19 Sürecinde Hipertansiyon Hastaları İçin Neler Yapalım?". Kardiyovasküler Hemşirelik Dergisi 12/27 (2021), 52-58.